Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xomed

This article was originally published in The Gray Sheet

Executive Summary

Three-for-two stock split is effective Nov. 16. The additional shares will be distributed on Nov. 30 through a stock dividend of one additional common share for every two shares of Xomed stock held. "The stock split is designed to provide a trading price range that is accessible to a broader group of investors," Xomed explains. Third-quarter 1998 results announced in conjunction with the split show a 17.5% sales increase to $21.9 mil. Net income is up 62% to $2.2 mil. The company's flagship XPS model 2000 StraightShot power resection system, used in least invasive endoscopic sinus surgery as well as certain head and neck procedures "continues to receive strong market acceptance with a global installed base of over 1,500 units at the end of the third quarter," the firm reports

You may also be interested in...



US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.

UsernamePublicRestriction

Register

MT010992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel